If I look at UBS activity in all Pharma and Biotech, Neuren is by far an outlier. The data contains companies with different market caps but for example they have sold more than 2.8x the amount of NEU as they have bought any other share over the same period of time, including TLX which is a 8.8bn company that's up over 100% in the same time period. I don't think this is regular trading given the volumes here relative to much larger companies like TLX, CSL etc.
Ann: Update - Notification of buy-back - NEU, page-31
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.96 |
Change
-0.140(1.07%) |
Mkt cap ! $1.612B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.36 | $12.82 | $4.627M | 354.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7585 | $12.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.03 | 3344 | 2 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |